scholarly journals Therapeutic Trial of Rifabutin After Rifampicin-Associated DRESS Syndrome in Tuberculosis-Human Immunodeficiency Virus Coinfected Patients

2016 ◽  
Vol 3 (3) ◽  
Author(s):  
Rannakoe J. Lehloenya ◽  
Sipho Dlamini ◽  
Rudzani Muloiwa ◽  
Betty Kakande ◽  
Mzudumile R. Ngwanya ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Clinical Management ◽  
Cross Reactivity ◽  
Therapeutic Trial ◽  
Drug Reactions ◽  
Dress Syndrome ◽  
Drug Eruptions ◽  
Immunodeficiency Virus ◽  
Drug Rash ◽  
Systemic Symptoms

Abstract Elimination of a rifamycin from the treatment regimen for tuberculosis negatively impacts outcomes. Cross-reactivity between the rifamycins after drug eruptions is unclear. We report 6 consecutive human immunodeficiency virus-infected patients with rifampicin-associated drug rash with eosinophilia and systemic symptoms (DRESS) syndrome confirmed on diagnostic rechallenge. The patients subsequently tolerated rifabutin. These data inform clinical management of tuberculosis-associated drug reactions.

Drug Rash With Eosinophilia and Systemic Symptoms (DRESS) Syndrome Probably Related to Cefpodoxime: A Case Report

2019 ◽  
pp. 089719001986609 ◽  
Author(s):  
Tirin Babu ◽  
George Mathew Panachiyil ◽  
Juny Sebastian ◽  
Veeranna Shastry
Keyword(s):  
Case Report ◽  
Signs And Symptoms ◽  
Side Effect Profile ◽  
Drug Reactions ◽  
Dress Syndrome ◽  
First Case ◽  
Drug History ◽  
Drug Rash ◽  
Systemic Symptoms ◽  
Favorable Side Effect Profile

Cefpodoxime is a common antibiotic with a favorable side effect profile. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described with several cephalosporins but not cefpodoxime. We report the probable first case of cefpodoxime-induced DRESS syndrome in a 52-year-old female patient. In our case, the patient presented with symptoms of DRESS syndrome 16 days after initiation of cefpodoxime. This case highlights the necessity of consideration of an iatrogenic reason for presenting signs and symptoms at all times. Reinforcing the importance of taking a thorough drug history and considering drug reactions even if onset of symptoms are delayed.

Dolutegravir as a trigger for DRESS syndrome?

2018 ◽  
Vol 29 (10) ◽  
pp. 1036-1038 ◽  
Author(s):  
Charlotte Martin ◽  
Marie-Christine Payen ◽  
Stephane De Wit
Keyword(s):  
Human Immunodeficiency Virus ◽  
Drug Reaction ◽  
Second Generation ◽  
Strand Transfer ◽  
Dress Syndrome ◽  
Immunodeficiency Virus ◽  
Transfer Inhibitor ◽  
Inhibitor Drug ◽  
Systemic Symptoms ◽  
Integrase Strand Transfer Inhibitor

Dolutegravir is an increasingly-used second-generation human immunodeficiency virus integrase strand transfer inhibitor. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) syndrome has been described in several patients treated with raltegravir but to our knowledge, there is no previous report of DRESS syndrome associated with dolutegravir.

scholarly journals A case of a drug reaction to sulfasalazine in a patient infected with HIV

2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Leanne Swart ◽  
Elise Schapkaitz ◽  
Anima Baiden
Keyword(s):  
Rheumatoid Arthritis ◽  
Human Immunodeficiency Virus ◽  
Drug Reaction ◽  
Supportive Treatment ◽  
Drug Reactions ◽  
Infected Female ◽  
Immunodeficiency Virus ◽  
Systemic Symptoms ◽  
Multiple Drugs ◽  
Made In

Introduction: The diagnosis of drug reaction with eosinophilia and systemic symptoms (DRESS) in human immunodeficiency virus (HIV) patients on multiple drugs with concomitant disorders presents a diagnostic challenge.Patient presentation: We describe a case of a drug reaction to sulfasalazine in a 46 year old HIV-infected female with concurrent rheumatoid arthritis which presented atypically with a marked peripheral blood plasmacytosis mimicking a lymphoproliferative neoplasm.Management and outcome: A diagnosis of DRESS was made in conjunction with the laboratory and clinical presenting findings. Sulfasalazine was immediately discontinued. The mucocutaneous rash and systemic symptoms (which included fever, lymphadenopathy and multi-organ dysfunction) resolved with supportive treatment. This included topical and systemic corticosteroids.Conclusion: In conclusion, it is important to consider drug reactions when evaluating patients infected with HIV.

scholarly journals Raltegravir-associated Drug-Reaction With Eosinophilia and Systemic Symptoms Syndrome in a Pediatric Patient Without Characteristic Human Leukocyte Antigen B*57:01 or B*53:01 alleles

2020 ◽  
Author(s):  
Sanya J Thomas ◽  
Jacob T Kilgore ◽  
Bradford A Becken ◽  
Coleen K Cunningham ◽  
Amelia B Thompson
Keyword(s):  
Drug Reaction ◽  
Human Leukocyte Antigen ◽  
Human Leukocyte ◽  
African American Female ◽  
Dress Syndrome ◽  
Leukocyte Antigen ◽  
Antigen B ◽  
Immunodeficiency Virus ◽  
Perinatally Acquired ◽  
Systemic Symptoms

Abstract We present the first published case of raltegravir-associated drug-reaction with eosinophilia and systemic symptoms (DRESS) syndrome in a child without characteristic human leukocyte antigen haplotypes HLA-B*57:01 or HLA-B*53:01. A 4-year-old African American female with perinatally acquired human immunodeficiency virus infection was hospitalized for DRESS after starting a raltegravir-based antiretroviral regimen.

Sign in / Sign up

Export Citation Format

Share Document